OCUGEN, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
OCUGEN, INC. (OCGN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $900.00 thousand as of 2017-12-31, per its 10-K filed 2019-03-22.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2019-03-22
- 2017-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $900.00K.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2017-12-31 | $900.00K 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |